On the fly News and insights, exclusive to thefly.com

2019-08-21 10:10:45 CREE Cree $52.88 / -5.31 (-9.13%) , HA Hawaiian Holdings $23.94 / -1.5 (-5.90%) … 10:10 08/21/19 08/21 10:10 08/21/19 10:10	Fly Intel: Top five analyst downgrades Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Cree (CREE) downgraded to Market Perform from Outperform at JMP Securities with analyst Joseph Osha saying the company has forecasted soft business conditions to persist into the quarter. 2. Hawaiian Holdings (HA) double downgraded to Sell from Buy at Stifel with analyst Joesph DeNardi citing 2020 earnings risk. 3. Chimera (CIM) downgraded to Neutral from Outperform at Credit Suisse with analyst Douglas Harter citing valuation. 4. Synlogic (SYBX) downgraded to Sell from Buy at Citi and to Perform from Outperform at Oppenheimer. 5. Jazz Pharmaceuticals (JAZZ) downgraded to Neutral from Overweight at Piper Jaffray with analyst David Amsellem citing his survey of 30 current prescribers of Xyrem in order to gauge whether there will be physician appetite for using recently approved Wakix, either in replacement or in combination. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here. CREE Cree $52.88 / -5.31 (-9.13%) HA Hawaiian Holdings $23.94 / -1.5 (-5.90%) CIM Chimera $19.52 / -0.17 (-0.86%) SYBX Synlogic $3.25 / -0.22 (-6.34%) JAZZ Jazz Pharmaceuticals $134.12 / -2.42 (-1.77%)	04 Sep 04 Sep 05 Sep 09 Sep 30 Oct

2019-08-21 10:10:45

CREE

Cree

$52.88 / -5.31 (-9.13%)

, HA

Hawaiian Holdings

$23.94 / -1.5 (-5.90%)

… 10:10

08/21/19

08/21

10:10

08/21/19

10:10

Fly Intel: Top five analyst downgrades

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Cree (CREE) downgraded to Market Perform from Outperform at JMP Securities with analyst Joseph Osha saying the company has forecasted soft business conditions to persist into the quarter. 2. Hawaiian Holdings (HA) double downgraded to Sell from Buy at Stifel with analyst Joesph DeNardi citing 2020 earnings risk. 3. Chimera (CIM) downgraded to Neutral from Outperform at Credit Suisse with analyst Douglas Harter citing valuation. 4. Synlogic (SYBX) downgraded to Sell from Buy at Citi and to Perform from Outperform at Oppenheimer. 5. Jazz Pharmaceuticals (JAZZ) downgraded to Neutral from Overweight at Piper Jaffray with analyst David Amsellem citing his survey of 30 current prescribers of Xyrem in order to gauge whether there will be physician appetite for using recently approved Wakix, either in replacement or in combination. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

CREE

Cree